Benjamin Andrick, PharmD, BCOP
Research Interests
Benjamin Andrick, PharmD, BCOP is an assistant professor, clinical research within the Center for Pharmacy Innovation and Outcomes, assistant director of Geisinger’s Hematology/Oncology Pharmacy program, and director of the Oncology PGY2 Residency Program. Originally from Lancaster, PA, he completed his Doctor of Pharmacy degree at Duquesne University in Pittsburgh, PA. Subsequently, he completed his PGY1 and PGY2 oncology residency training at Augusta University Medical Center, in collaboration with the University of Georgia College of Pharmacy, in Augusta, GA. He has a particular interest in hematological malignancies and hematopoietic stem cell transplantation as well as pharmacy practice services. Additionally, his clinical research interests include hematological malignancies/HCT supportive care, vaccines and the impact of the hem/onc pharmacist on clinical and pharmacoeconomic outcomes.
Recent Publications
- Andrick B, Tusing L, Jones J, Hu Y, Sneidman R, Gregor C, Basu S, Lynch JP, Vadakara J. The impact of a hematopoietic cellular therapy pharmacist on clinical and humanistic outcomes: A RE-AIM framework analysis. Transplant Cell Ther. 2022 Jun;28(6):334.e1-334.e9. Full Text
- Mathur A, Maiers T, Andrick B. Impact of a pharmacist-led telehealth oral chemotherapy clinic. Am J Health Syst Pharm. 2022 May 24;79(11):896-903. Full Text
- Okubo L, Andrick B, Rampulla R, Leri F. Smaller but more frequent dosing of cefepime in the treatment of febrile neutropenia. J Oncol Pharm Pract. 2022 Jun;28(4):898-903. Full Text
- Hart K, Andrick B, Grassi S, Manikowski J, Graham J. Cancer-Associated Venous Thromboembolism Treatment With Anti-Xa Versus Weight-Based Enoxaparin: A Retrospective Evaluation of Safety and Efficacy. Ann Pharmacother. 2021 Sep;55(9):1120-1126. Full Text
- Lee GW, Mathur AD, Andrick BJ, Leese E, Zally D, Gatson NN. Pharmacist value-added to neuro-oncology subspecialty clinics: A pilot study uncovers opportunities for best practices and optimal time utilization. J Oncol Pharm Pract. 2020 Dec;26(8):1937-1941. Full Text
- Marjoncu D, Andrick B. Gilteritinib: A Novel FLT3 Inhibitor for Relapsed/Refractory Acute Myeloid Leukemia. J Adv Pract Oncol. 2020 Jan-Feb;11(1):104-108. Full Text
- Tunzo N, Andrick B. Professional Development for the Practicing Pharmacist: Using the FINER Criteria to Evaluate Your Research Question. Pennsylvania Pharmacist. Vol 100, Issue 5. September/October 2019. Full Text
Education
Doctor of Pharmacy, Duquesne University, 2015
PGY1 and PGY2 Oncology Pharmacy Residency, Augusta University Medical Center/University of Georgia College of Pharmacy, 2016, 2017
BPS Board Certified Oncology Pharmacist, 2018